James Raschko

1.5k total citations
50 papers, 1.1k citations indexed

About

James Raschko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, James Raschko has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in James Raschko's work include Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). James Raschko is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). James Raschko collaborates with scholars based in United States. James Raschko's co-authors include Kim Margolin, George Somlo, James H. Doroshow, Robert J. Morgan, Steven A. Akman, Lucille Leong, Merry Tetef, Chul Ahn, Stephen Shibata and L. Leong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

James Raschko

50 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Raschko United States 20 416 223 212 179 179 50 1.1k
Ian G. Kerr Canada 16 590 1.4× 276 1.2× 225 1.1× 175 1.0× 131 0.7× 37 1.3k
ES Newlands United Kingdom 16 258 0.6× 388 1.7× 336 1.6× 120 0.7× 29 0.2× 38 1.0k
B.M.J. Cantwell United Kingdom 19 421 1.0× 172 0.8× 338 1.6× 138 0.8× 33 0.2× 52 1.1k
R. de las Peñas Spain 15 438 1.1× 163 0.7× 330 1.6× 460 2.6× 43 0.2× 63 1.1k
P Cappelaere France 15 395 0.9× 267 1.2× 140 0.7× 216 1.2× 49 0.3× 66 855
Julio Hajdenberg United States 14 261 0.6× 626 2.8× 259 1.2× 309 1.7× 68 0.4× 38 1.1k
Giuseppina Catalano Italy 28 1.4k 3.4× 377 1.7× 268 1.3× 835 4.7× 42 0.2× 72 2.2k
Graydon Harker United States 11 647 1.6× 509 2.3× 179 0.8× 188 1.1× 39 0.2× 15 1.2k
Stefan Madajewicz United States 20 875 2.1× 349 1.6× 236 1.1× 484 2.7× 23 0.1× 63 1.5k
K. Buser Switzerland 12 409 1.0× 323 1.4× 130 0.6× 111 0.6× 18 0.1× 17 875

Countries citing papers authored by James Raschko

Since Specialization
Citations

This map shows the geographic impact of James Raschko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Raschko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Raschko more than expected).

Fields of papers citing papers by James Raschko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Raschko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Raschko. The network helps show where James Raschko may publish in the future.

Co-authorship network of co-authors of James Raschko

This figure shows the co-authorship network connecting the top 25 collaborators of James Raschko. A scholar is included among the top collaborators of James Raschko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Raschko. James Raschko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Robert J., Edward M. Newman, Lawrence C. Sowers, et al.. (2003). Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 51(6). 459–464. 14 indexed citations
2.
Somlo, George, Jean F. Simpson, Paul Frankel, et al.. (2002). Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. British Journal of Cancer. 87(3). 281–288. 22 indexed citations
3.
Morgan, R.J., L. Leong, J R Schriber, et al.. (2001). Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplantation. 28(9). 859–863. 6 indexed citations
4.
Lara, Primo, David R. Gandara, Jeff Longmate, et al.. (2001). Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemotherapy and Pharmacology. 48(1). 22–28. 20 indexed citations
5.
6.
Tetef, Merry, Kim Margolin, James H. Doroshow, et al.. (2000). Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemotherapy and Pharmacology. 46(1). 19–26. 75 indexed citations
7.
Tetef, Merry, Lucille Leong, Chul Ahn, et al.. (1999). Cisplatin and Infusional Cytosine Arabinoside for the Treatment of Colorectal Adenocarcinoma: A Phase II Trial. Cancer Investigation. 17(2). 114–117. 2 indexed citations
8.
Lara, Primo N., David R. Gandara, Gregory T. Wurz, et al.. (1998). High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemotherapy and Pharmacology. 42(6). 504–508. 8 indexed citations
9.
Somlo, George, James H. Doroshow, Stephen J. Forman, et al.. (1997). High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.. Journal of Clinical Oncology. 15(8). 2882–2893. 63 indexed citations
10.
Demetri, G. D., Anthony Elias, D. M. Gershenson, et al.. (1996). NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.. PubMed. 10(11 Suppl). 179–94. 41 indexed citations
11.
Tetef, Merry, Kim Margolin, Chul Ahn, et al.. (1995). Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Investigational New Drugs. 13(2). 157–162. 47 indexed citations
12.
Margolin, Kim, Steven A. Akman, Lucille Leong, et al.. (1995). Phase I study of mitomycin C and menadione in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 36(4). 293–298. 38 indexed citations
13.
Margolin, Kim, Steven A. Akman, Lucille Leong, et al.. (1995). Phase I study of mitomycin C and menadione in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 36(4). 293–298. 2 indexed citations
14.
Morgan, Robert J., James L. Speyer, James H. Doroshow, et al.. (1995). Modulation of 5-Fluorouracil with High-Dose Leucovorin Calcium: Activity in Ovarian Cancer and Correlation with CA-125 Levels. Gynecologic Oncology. 58(1). 79–85. 18 indexed citations
15.
Raschko, James, Steven A. Akman, Lucille Leong, et al.. (1994). Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemotherapy and Pharmacology. 35(2). 161–164. 4 indexed citations
16.
Margolin, Kim, James H. Doroshow, Steven A. Akman, et al.. (1992). Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.. Journal of Clinical Oncology. 10(8). 1278–1283. 18 indexed citations
17.
Newman, Edward M., Steven A. Akman, Jonathan S. Harrison, et al.. (1992). Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.. PubMed. 52(9). 2408–12. 18 indexed citations
18.
Raschko, James, Elizabeth A. Johnson, Winston Ueno, Paul V. Woolley, & Joseph Treat. (1991). Continuous Infusion 5-Fluorouracil with Bolus Adriamycin and Mitomycin and Low-Dose Cisplatin (FAMP) in the Treatment of Metastatic Gastric Carcinoma: An Evaluation of Efficacy and Toxicity. Cancer Investigation. 9(1). 49–51. 4 indexed citations
19.
Vokes, Everett E., James Raschko, Nicholas J. Vogelzang, et al.. (1991). Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemotherapy and Pharmacology. 28(1). 69–73. 9 indexed citations
20.
Taylor, Addison A., Albert O. Davies, James Raschko, et al.. (1989). Spectrum of dysautonomia in mitral valvular prolapse. The American Journal of Medicine. 86(3). 267–274. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian G. Kerr Breakdown of academic impact, for papers by ES Newlands Breakdown of academic impact, for papers by B.M.J. Cantwell Breakdown of academic impact, for papers by R. de las Peñas Breakdown of academic impact, for papers by P Cappelaere Breakdown of academic impact, for papers by Julio Hajdenberg Breakdown of academic impact, for papers by Giuseppina Catalano Breakdown of academic impact, for papers by Graydon Harker Breakdown of academic impact, for papers by Stefan Madajewicz Breakdown of academic impact, for papers by K. Buser
Rankless by CCL
2026